The proposed K12 grant application is derived directly from The Ohio State University Comprehensive Cancer Center's (OSU CCC) fundamental focus on experimental therapeutics and drug development. Over the past decade the OSU CCC has expanded dramatically its highly successful recruitment of both basic and clinical scientists focused on different aspects of drug development. The end results of these efforts are the multiple, new therapeutics coming forth to clinical trials at OSU through its NCI-sponsored UO1 and N01 grants programs. Additionally, investigators at the OSU CCC have collaborated extensively with industry to perform clinical trials with new therapeutics for patients with cancer. This established infrastructure of basic and clinical scientists working together in the area of cancer experimental therapeutics provides an outstanding atmosphere for the training of basic translational scientists and clinical translational scientists in medical oncology and surgical oncology. Support for such training will provide a cadre of well-trained individuals dedicated to the development of new diagnostic devices and therapies that ultimately will benefit patients with cancer. The overall goal of this K12 grant entitled """"""""Experimental Therapeutics in Cancer"""""""" is therefore to provide training and effective writing and verbal communicative/interactive skills to faculty level basic translational and clinical translational scientists who will dedicate their endeavors to cancer translational research. Based upon the overall strength of the OSU CCC in the area of experimental therapeutics and the true desire of many involved faculty to mentor junior faculty, this K12 proposal seeks to train primarily two types of assistant professors focused on translational work in experimental therapeutics: 1] The first group includes MD or PhD faculty who have outstanding basic science training and the desire to pursue laboratory investigation related to applied research in experimental therapeutics of solid tumor or hematologic malignancies;2] The second group includes MD or MD/PhD faculty who pursue patient-related research in clinically focused experimental therapeutics. The two oncology disciplines that such trainees come from are medical and surgical oncology. The primary aims of this K12 training grant proposal include: Objective 1: To provide individualized faculty level training to ensure a cadre of translational medical doctors and basic science researchers who can collaborate with each other to design and implement hypothesis-driven experimental therapeutic research directed at patients with cancer. Objective 2: To provide applicants with a core course work of biostatistical, pharmacology, pharmacodynamic, clinical trial, grant writing, and professional education classes that will assure successful transition to faculty level positions focused on experimental therapeutics at academic NCI-designated cancer centers. To attain these objectives we have designed a structured program that objectively selects and mentors candidates through an innovative experiential process here at the OSU CCC. Applicants are initially selected through a competitive process by a K12 Steering Committee. Formal training follows that includes laboratory and clinical components derived from three different Colleges within The Ohio State University. These formal didactics and training episodes related to pre-clinical drug investigation and clinical protocol development provide instruction on the skills necessary to be an effective, well-rounded investigator in the area of experimental therapeutics. A continuous evaluation process of both K12 candidates and mentors is also outlined to assure that continued progress occurs among all those participating in this program. In addition, considerable institutional support that has been put forth by the OSU CCC, the James Cancer Hospital, and multiple OSU Medical Center Departments. Ultimately, this support will lead to the success of this K12 grant as measured by its ability to train the next generation of MD and PhD scientists in the focused area of cancer experimental therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
3K12CA133250-04S1
Application #
8244660
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
2008-09-09
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
4
Fiscal Year
2011
Total Cost
$171,008
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Miller, Eric D; Fisher, James L; Haglund, Karl E et al. (2018) The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol 13:426-435
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rosko, Ashley E; Huang, Ying; Benson, Don M et al. (2018) Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. J Geriatr Oncol :
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Zhang, Jiu-Cheng; Chen, Wei-Dong; Alvarez, Jean Bustamante et al. (2018) Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacol Sin 39:1693-1698
Narayanan, Ramesh; Coss, Christopher C; Dalton, James T (2018) Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol 465:134-142
Maini, Rohit; Wong, David B; Addison, Daniel et al. (2018) Persistent Underrepresentation of Kidney Disease in Randomized, Controlled Trials of Cardiovascular Disease in the Contemporary Era. J Am Soc Nephrol 29:2782-2786
Shukuya, Takehito; Patel, Sandipkumar; Shane-Carson, Kate et al. (2018) Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy. J Thorac Oncol 13:e17-e19
Chen, James L; David, Jason; Cook-Spaeth, Douglas et al. (2017) Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. Mol Cancer Res 15:26-34
Wesolowski, Robert; Duggan, Megan C; Stiff, Andrew et al. (2017) Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immunother 66:1437-1447

Showing the most recent 10 out of 184 publications